Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21F2N3O |
Molecular Weight | 345.3863 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@]([H])(C1)C3=C2N(N=C3C(=O)NC(C)(C)C)C4=C(F)C=C(F)C=C4
InChI
InChIKey=NTPZXHMTJGOMCJ-WDEREUQCSA-N
InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
Molecular Formula | C19H21F2N3O |
Molecular Weight | 345.3863 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Glenmark Pharmaceuticals has developed tedalinab (also known as GRC-10693) as a potent and selective cannabinoid CB2 receptor agonist for the treatment of osteoarthritis and neuropathic pain. In April 2009, Glenmark announced that tedalinab indicated for the treatment of neuropathic, osteoarthritis and other inflammatory pain disorders had successfully completed Phase I trials in Europe. The drug was ready for phase II of trials; however, information about the further development of this drug is not available.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 07:34:21 UTC 2022
by
admin
on
Sat Dec 17 07:34:21 UTC 2022
|
Record UNII |
5R7X34Y6Q1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
67029278
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
DTXSID801030347
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
CHEMBL3234681
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
9257
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
Tedalinab
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
C152534
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
5R7X34Y6Q1
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY | |||
|
916591-01-0
Created by
admin on Sat Dec 17 07:34:21 UTC 2022 , Edited by admin on Sat Dec 17 07:34:21 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
very high selectivity of 4700x for CB2 over the related CB1 receptor
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |